In the US, the estimated number of people over 18 years of age with diagnosed and undiagnosed diabetes is 30.2 million. Without ongoing, careful management, diabetes can lead to a buildup of sugars in the blood, which can increase the risk of dangerous complications, including stroke and heart disease.
- FPG 100mg/dL (5.6mmol/L) to 125 mg/dL (6.9mmol/L) IFG
- 2-h during PG during 75-g OGTT 140mg/dL (7.8mmol/L) to 199mg/dL (11.0mmol/L) (IGT)
- A1C 5.7-6.4% (39-47 mmol/mol)
- glycosylated hemoglobin (HbA1c), fasting plasma glucose (FGP) levels, oral glucose tolerance test (OGTT)
- salivary biomarkers (α2- macroglobulin, melatonin, α-hydroxybutyrate, glucose) and HbA1c
- cardiovascular biomarkers, (high sensitivity troponin (hs-trop) and B- natriuretic peptide (BNP)
- polymorphisms in particular genes (e.g. PPARG, KCNJ11, TCF7L2, CDKAL1, HHEX, SLC30A8, IGF2BP2, CDKN2A)
- measuring A1c at a minimum of twice yearly for patients meeting treatment goals and
- at least quarterly in patients not meeting goals or with changes in therapy.
Detect Chronic Kidney Disease (CKD)
- estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2
- urinary albumin-to-creatinine ratio (UACR) <10 mg/g
Cardiovascular Risk Stratification
- Glycemic Metrics (A1c)
- Renal Biomarkers (eGFR, UACR)
- Cardiac Biomarkers (increased concentrations of natriuretic peptides and CRP, decreased concentrations of circulating troponin)
is a carefully validated, clinically realistic model for early diabetes mellitus screening and managing of the disease.
Our mathematical & computational tools
enable researchers and decision makers to make better informed decisions.